AbbVie's Telisotuzumab Adizutecan Receives Two FDA Breakthrough Therapy Designations for Colorectal and Non-Small Cell Lung Cancers

AbbVie announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab-A) for the treatment of colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). These designations aim to expedite the development and review of this investigational medicine, which has shown potential in multiple solid tumors.